register

Human Resources

Microsoft trial of a 4-day workweek shows productivity boost of 40%

Health Industry Hub | November 6, 2019 |

An experiment that involved reducing the workweek by one day led to a 40% boost in productivity in a Microsoft subsidiary in Japan, the technology giant announced last week.

The trial was part of Microsoft’s “Work-Life Choice Challenge,” a summer project that examined work-life balance and aimed to help boost creativity and productivity by giving employees more flexible working hours.

Microsoft Japan closed its offices every Friday in August and found that labor productivity increased by 39.9% compared with August 2018, the company said. Full-time employees were given paid leave during the closures.

The company said it also reduced the time spent in meetings by implementing a 30-minute limit and encouraging remote communication.

Studies have found there’s demand for a shorter workweek. Last year, in a study of nearly 3,000 workers in eight countries by the Workforce Institute at Kronos and Future Workplace, most said their ideal workweek would be four days or less.

It’s not just the employees who benefited from Microsoft’s four-day-workweek experiment – Microsoft found that it helped preserve electricity and office resources as well. The number of pages printed decreased by 58.7%, while electricity consumption was down by 23.1% compared with August 2018, the company said.

You may also like Braving; The seven elements of trust

Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.